Ovarian Cancer

Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors

European Oncology & Haematology. 2019;15(1):29–40 DOI: https://doi.org/10.17925/EOH.2019.15.1.29

Worldwide, ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer death in women.1 The GLOBOCAN study estimated there were 239,000 new cases in 2012 and 152,000 deaths due to this disease. There are nearly 600,000 women living within 5 years of an ovarian cancer diagnosis.1 In the EU, age-adjusted ovarian […]

Advances in the Treatment of Endometrial and Ovarian Cancer

Oncology & Hematology Review. 2019;15(1):23–4 DOI: https://doi.org/10.17925/OHR.2019.15.1.23

Gynecological malignancies can be difficult to treat. Ovarian cancer carries with it the worst prognosis of all gynecological cancers. Approximately 75% of patients with epithelial ovarian cancer are diagnosed with advanced disease which is curable only in a minority of cases, resulting in a 5-year overall survival rate of only 20–30%. However, survival at all […]

touchINSIGHT

Olaparib as a Maintenance Therapy for Ovarian Cancer and its use in BRCA-related Metastatic Breast Cancer

Recent results from trials with olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, are discussed in this Insight. Positive data and regulatory approvals are demonstrating that targeting the underlying genetic causes of a cancer can be a powerful tool for the development of new treatments with efficacy across different cancer types.

Bevacizumab in the Management of Epithelial Ovarian Cancer

Oncology & Hematology Review (US), 2013;9(2):129–131 DOI: https://doi.org/10.17925/OHR.2013.09.2.129

Epithelial ovarian cancer has long been recognized as being highly sensitive to cytotoxic chemotherapy, with anticipated objective response to platinum-based chemotherapy of approximately 70-85%1. Furthermore, overall survival (OS) for women presenting with advanced disease has been documented to have improved over the past few decades,2 although unfortunately the majority of responding patients ultimately experience recurrence […]

Squamous Cell Carcinoma Arising in a Mature Cystic Teratoma of the Ovary: A Case Series and Review of the Literature

European Oncology & Haematology, 2013;9(1):17–20 DOI: https://doi.org/10.17925/EOH.2013.09.1.17

Mature cystic teratomas (also called dermoid cysts) account for about 30–45 % of all ovarian neoplasms and around 60 % of all benign tumours arising in the ovary.1 Malignant transformation of the various mature tissue components of a dermoid cyst is rare and the reported incidence is 0.17–1.4 %.2,3 Squamous cell carcinoma (SCC), arising from […]

NGR-hTNF plus Doxorubicin in Relapsed Ovarian Carcinoma

European Oncology & Haematology, 2013;9(1):9–12 DOI: https://doi.org/10.17925/EOH.2013.09.1.9

Ovarian cancer (OC) is the most lethal gynaecological cancer. In 2010, approximately 21,880 new cases and 13,850 deaths occurred in the US,1 while in the EU in 2004 the incidence of newly diagnosed cases was 42,700 with a mortality of 12/100,000 women/year.2 The current treatment of OC involves aggressive cytoreductive surgery followed by platinum- and […]

NGR-hTNF plus Doxorubicin in Recurrent Ovarian Cancer

European Oncology & Haematology, 2012;8(2):107–10 DOI: https://doi.org/10.17925/EOH.2012.08.02.107

Ovarian cancer is the most lethal gynaecological cancer. In the US, approximately 21,880 new cases were identified and 13,850 women died of the disease in 2010.1 In the European Union, the number of newly diagnosed cases was 42,700 in 2004 and the mortality rate is 12 per 100,000 women per year.2 The current treatment for […]

First-line Chemotherapy in Patients with Advanced Ovarian Cancer

US Oncological Disease, 2007;1(2):71-2 DOI: https://doi.org/10.17925/OHR.2007.00.2.71

Ovarian cancer is the fifth most common malignancy in women. In the US, approximately 22,000 new cases occur each year.1 In Germany, about 8,000 new cases are diagnosed each year. About 80% of patients suffer from advanced-stage disease (International Federation of Gynaecology and Obstetrics [FIGO] III/IV) with an unfavorable prognosis. Due to the lack of […]

Phenoxodiol—A Chemosensitizer in the Midst of Cancer Chemoresistance

US Oncological Review, 2008;4(1):39-41 DOI: https://doi.org/10.17925/OHR.2008.04.1.39

Phenoxodiol ([2H-1-Benzopyran-7-ol, 3-(4-hydrophyphenyl] (PXD) is a synthetic derivative of genistein, a naturally occurring plant isoflavone. In the 1980s, genistein was discovered to have modest anticancer activity, and alterations in its structure created PXD and increased its anticancer activity without any toxicity. In vitro and in vivo studies showed PXD not only to be directly cytotoxic […]